An interventional study of Combination Prebiotic and Postbiotic in Weight Loss, Metabolic Health and Quality of Life, sponsored by Able Biolabs, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Able Biolabs, LLC · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,000 studies in Weight Loss with a site in United States — 119 open to participants now, 174 under way, 9 of them phase 3. Weight Loss · United States.
Among the 1,000 studies in Weight Loss with a site in United States, this one is the 776th largest by enrollment of the 917 interventional ones that give a count, is one of 50 that started in 2026, is one of 714 with no phase, and was the 977th registered.
1,821 studies on the registry are indexed under Weight Loss; 299 are open to participants now.
Browse Weight Loss studies →119 of the 1,000 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 200 Weight Loss studies recruiting now, 74 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,000 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 107 · Phase 3 41 · Phase 4 34
First in 1996; this study’s year is marked. 50 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 1,567 interventional studies indexed under Weight Loss.
Median enrollment 72 across the 917 interventional studies, 99 across the 76 observational. Of the 769 that completed or were terminated, 232 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 1,000 have an industry lead sponsor. The 10 most frequent:
Able Biolabs, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.
Able Biolabs, LLC has 1 study filed under Weight Loss — fewer than ten, so there is no comparison to draw.
58 of the studies in Weight Loss with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT07223242Phase 3University of Texas Southwestern Medical CenterTailored Exercise Training Study Among Adults With HFpEF | 2026-12-30 |
| NCT07104383Phase 3Viking Therapeutics, Inc.VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | 2027-07-01 |
| NCT07104500Phase 3Viking Therapeutics, Inc.VK2735 for Weight Management Phase 3 | 2027-07-01 |
| NCT07560579Million Marker Wellness, Inc.Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity | 2026-11 |
Add all 58 to your calendar (.ics) → With an account.
Among the 1,000 studies in Weight Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This consumer-use study evaluates the effects of a combined postbiotic and prebiotic supplement regimen on appetite control, cravings, metabolic health, energy, and quality of life in adults aged 18-65 years with a body mass index (BMI) between 25 and 30.
Participants will consume one capsule of resM™ GLP-1 Postbiotic and one scoop of resG prebeet ENERGY Prebiotic daily for 60 days. Data will be collected through daily check-ins, weekly surveys, and quality-of-life questionnaires administered through the Chloe mobile application.
The primary objective is to evaluate changes in appetite control and food cravings over 60 days of supplementation.
The GLP-1 Optimizer Bundle combines resM™ GLP-1 Postbiotic and resG prebeet ENERGY Prebiotic to support appetite control, cravings, metabolic health, energy, and lifestyle behaviors.
This is a prospective, open-label, single-arm consumer-use study conducted over 60 days in approximately 20 adults aged 18-65 years with BMI between 25 and 30.
Participants will consume:
one capsule of resM™ GLP-1 Postbiotic daily one scoop of resG prebeet ENERGY Prebiotic daily
Assessments will be collected electronically through the Chloe mobile application and include:
appetite and cravings surveys energy and mood assessments quality-of-life questionnaires lifestyle habit surveys consumer satisfaction assessments
The study aims to evaluate consumer-reported changes associated with daily supplementation and lifestyle guidance.
Inclusion Criteria:
Adults aged 18-65 years between 25 and 30 Generally healthy Willing to comply with study procedures Access to smartphone or internet-enabled device for electronic questionnaires
Exclusion Criteria Pregnant, planning pregnancy, or lactating History of bariatric surgery Prescription weight loss medication use within the past 90 days Current GLP-1 drug use History of substance abuse within the past 6 months Current use of supplements containing overlapping active ingredients Significant medical condition that may interfere with study participation or interpretation of results
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
resM™ GLP-1 Postbiotic, and resG prebeet ENERGY Prebiotic
Dietary Supplement: Combination Prebiotic and Postbiotic
Participants will take a combined dosage of prebiotic and postbiotic.
Change in Appetite Control and Food Cravings Survey Scores Over 60 Days
Participant-reported appetite control and food cravings will be assessed using daily and weekly questionnaires administered through the Chloe mobile application. Survey responses will evaluate changes in hunger, cravings, satiety, and eating behaviors over the study period.
Time frame: Baseline through Day 60
Change in Quality-of-Life Questionnaire Responses Over 60 Days
Quality-of-life assessments will evaluate participant-reported physical well-being, lifestyle habits, and overall satisfaction during the study period.
Time frame: Baseline, Day 30, and Day 60
Participant Satisfaction and Willingness to Recommend or Continue Product Use
At the end of the study, participants reported overall satisfaction, whether they would recommend the product bundle, whether they would continue using it, and open-ended feedback about their experience. These responses were self-reported and descriptive.
Time frame: End of Week 8
Change in Participant-Reported Body Weight
Participants reported body weight at baseline and weekly through Week 7. Percentage weight-loss thresholds, if included, are exploratory and descriptive.
Time frame: Baseline and weekly through Week 7
Adherence to Daily Supplement Use
Participants completed daily forms reporting use of the study products. Adherence was summarized as the percentage of planned daily use reported during the 60-day study.
Time frame: - Daily through Day 60
Participants Reporting Adverse Events
Adverse events were collected through daily forms. The outcome is the number of participants reporting an adverse event during the study, summarized by event and severity.
Time frame: Daily through Day 60
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in May 2026, 3 months.
Of 671 non-industry interventional studies with no phase under Weight Loss, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 3 months is below that.
Counting every sponsor, half of 730 studies reached it within 24 months; a quarter within 11 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Jan 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Able Biolabs, LLC